Elocom-S (mometasone furoate) ointment 15.0


Manufacturer: Jordan

Inflammatory phenomena and itching in dermatoses amenable to corticosteroid therapy, including psoriasis (except for common plaque psoriasis) and atopic dermatitis, in adults and children aged 2 yEars and Nose and older.

Out of stock



Elocom-S Storage
active substances: mometasone furoate, salicylic acid.

1 g of ointment contains mometasone furoate 1 mg and salicylic acid 50 mg;

Elocom-S Excipients: hexylene glycol, propylene glycol stearate (55% monoether), purified water, white soft paraffin, white wax.

Elocom-S Dosage form

Basic physical and chemical properties: homogeneous ointment of white or almost white color.

Pharmacotherapeutic group
Corticosteroids for use in dermatology. Active corticosteroids in combination with other drugs. ATX code D07X C03.

Pharmacological properties


Mechanism of action. Like other topical corticosteroids, mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive effects. The mechanism of anti-inflammatory action of corticosteroids for external use remains unclear.

Salicylic acid helps to exfoliate the stratum corneum without affecting the structure of the living epidermis. The mechanism of action is the dissolution of intercellular cement. Salicylic acid improves the absorption of mometasone furoate through the skin layers.

Pharmacodynamic effect. The pharmacodynamic activity of Elocom-C® is due to the active components of mometasone furoate and salicylic acid and excipients. Mometasone is a highly active glucocorticoid that belongs to class III according to the European classification.

One patient showed a decrease in plasma cortisol levels due to the use of about 7.5 g of Elocom-C® twice a day (daily dose – 15 g) for 7 days on 30% of the body surface area, indicating a slight effect on the hypothalamic-pituitary-adrenal (GGNZ) system.


Absorption. The degree of absorption and development of systemic effects depend on the following factors:

localization of the lesion and the condition of the epidermis;
duration of treatment;
lesion area;
use of occlusive dressings.
After a single topical application of Elocom-C® for 12 hours without the use of an occlusive dressing, approximately 1.5% of the administered dose is subject to systemic absorption. The average peak level of salicylic acid in blood plasma is 0.0066 mmol / l. Systemic toxic reactions to salicylic acid are usually observed at much higher concentrations (2.17-2.90 mmol / l).

After administration of approximately 7.5 g of Elocom-C® twice daily for 3 weeks without occlusive dressing, salicylate levels were less than 0.36 mmol / L, which is below the detection level. The laboratory norm for the concentration of salicylates in blood plasma, which is observed when administered orally and the appearance of systemic effects, is 1-2 mmol / l.

Biotransformation. Absorbed mometasone furoate is rapidly and extensively converted to numerous metabolites that have no pharmacological activity. No major metabolites have been isolated.

Breeding. Following a single application (12 hours) of a combination of 0.1% 3H-mometasone furoate and 5% salicylic acid to patients with psoriasis, approximately 0.36% and 1.11% of the radioactivity was detected in urine and faeces over a 5-day study. After appropriate use, the effective half-life of salicylic acid was 2.8 hours.

Treatment of moderate and severe plaque psoriasis.

Hypersensitivity to mometasone furoate, salicylic acid or to any other component of the drug.

Like other topical glucocorticoids, Elocom-C® is contraindicated in bacterial (including pyoderma, tuberculosis, syphilis), viral (herpes simplex, chicken pox, shingles, warts, genital warts, contagious or fungal infections) ), as well as in parasitic skin diseases, in the absence of concomitant adequate therapy.

Elocom-C® is also contraindicated in post-vaccination reactions, perioral dermatitis or rosacea, common acne and skin atrophy.